Activation of estrogen receptor α by estradiol and cisplatin induces platinum-resistance in ovarian cancer cells

ABSTRACT Activation of Estrogen receptor (ER) α (α) promotes cell growth and influences the response of cancer cell to chemotherapeutic agents. However, the mechanism by which ERα activation antagonizes cells to chemotherapy-induced cytotoxicity remains unclear. Here, we investigated the effect of cisplatin on ERα activation. In addition, we examined whether down-regulation of ERα modulate cisplatin-mediated cytotoxicity using 2 human ovarian cancer cells (Caov-3 and Ovcar-3) transduced with ERα short hairpin RNA (shRNA). The proliferation assay showed that 17β-estradiol (E2) induced cell proliferation via activation of Akt and extracellular signal-regulated kinase (ERK) cascades, while shRNA mediated downregulation of ERα inhibited the cell proliferation. Immunoblot analysis revealed that cisplatin induced the phosphorylation of ERα at serine 118 via ERK cascade. Luciferase assay showed that cisplatin increases transcriptional activity of estrogen-responsive element (ERE). The E2-stimulated ERα activation attenuated cisplatin-induced cytotoxicity. Meanwhile, down-regulation of ERα inhibited E2-induced protective effect on cisplatin toxicity as determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Moreover, Pretreatment with E2 followed by cisplatin decreased the expression of cleaved PARP, and increased the expression of anti-apoptotic protein Bcl-2. Collectively, our findings suggest that activation of ERα by E2 and cisplatin can induce platinum-resistance by increasing the expression of anti-apoptotic protein in ovarian cancer cells. Therefore, our findings provide valuable information that ERα might be a promising therapeutic target for platinum-resistant ovarian cancer.

[1]  B. Rowan,et al.  Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer , 2015, Molecular and Cellular Endocrinology.

[2]  K. Eng,et al.  Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer. , 2015, Gynecologic oncology.

[3]  M. Hendrix,et al.  Nodal signaling promotes a tumorigenic phenotype in human breast cancer. , 2014, Seminars in cancer biology.

[4]  Y. Otsuki,et al.  Regulation of bcl-2 transcription by estrogen receptor-α and c-Jun in human endometrium , 2014, Medical Molecular Morphology.

[5]  P. Tarapore,et al.  Estrogen receptor β isoform 5 confers sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis through interaction with Bcl2L12. , 2013, Neoplasia.

[6]  A. Mlynarcikova,et al.  Bisphenol A alone or in combination with estradiol modulates cell cycle- and apoptosis-related proteins and genes in MCF7 cells. , 2013, Endocrine regulations.

[7]  A. Sood,et al.  Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. , 2013, Gynecologic oncology.

[8]  Kazuhiro Takahashi,et al.  Non-sex cord-stromal ovarian tumors frequently produce and secrete estrogen in postmenopausal women: impact on bone metabolism and abnormal endometrial histology. , 2013, The Journal of clinical endocrinology and metabolism.

[9]  J. Slingerland,et al.  New insights on the role of hormonal therapy in ovarian cancer , 2013, Steroids.

[10]  A. Al-Niaimi,et al.  Epithelial ovarian cancer. , 2012, Obstetrics and gynecology clinics of North America.

[11]  Jian-guo Shen,et al.  The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells , 2012, Journal of experimental & clinical cancer research : CR.

[12]  W. Fan,et al.  Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors , 2012, Breast Cancer Research and Treatment.

[13]  P. Leung,et al.  Estrogen receptor alpha pathway is involved in leptin-induced ovarian cancer cell growth. , 2011, Carcinogenesis.

[14]  R. Broaddus,et al.  Molecular Clustering Based on ERα and EIG121 Predicts Survival in High-Grade Serous Carcinoma of the Ovary/Peritoneum , 2010, Modern Pathology.

[15]  S. Fox,et al.  Bisphenol A and estradiol are equipotent in antagonizing cisplatin-induced cytotoxicity in breast cancer cells. , 2010, Cancer letters.

[16]  A. Sood,et al.  Estrous Cycle Modulates Ovarian Carcinoma Growth , 2009, Clinical Cancer Research.

[17]  L. Downs,et al.  A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. , 2009, Gynecologic oncology.

[18]  M. Wakabayashi,et al.  Current Status on Biologic Therapies in the Treatment of Epithelial Ovarian Cancer , 2009, Current treatment options in oncology.

[19]  John F Smyth,et al.  Hormone therapy for epithelial ovarian cancer , 2008, Current opinion in oncology.

[20]  Takashi Suzuki,et al.  Intratumoral Estrogens and Estrogen Receptors in Human Non–Small Cell Lung Carcinoma , 2008, Clinical Cancer Research.

[21]  E. Henson,et al.  Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. , 2006, Cellular signalling.

[22]  Kazuhiro Takahashi,et al.  Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. , 2006, Endocrinology.

[23]  J. Hayakawa,et al.  Mechanisms of platinum drug resistance. , 2005, Trends in pharmacological sciences.

[24]  R. Schiff,et al.  Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. , 2005, Clinical Cancer Research.

[25]  T. Herzog.  Recurrent Ovarian Cancer , 2004, Clinical Cancer Research.

[26]  S. Kyo,et al.  Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines , 2004, Oncogene.

[27]  S. Hilsenbeck,et al.  Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth , 2002, Oncogene.

[28]  Kazuhiro Takahashi,et al.  Inhibition of Phosphorylation of BAD and Raf-1 by Akt Sensitizes Human Ovarian Cancer Cells to Paclitaxel* , 2002, The Journal of Biological Chemistry.

[29]  Simak Ali,et al.  Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera , 2002, Oncogene.

[30]  J. Hayakawa,et al.  Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. , 2000, Cancer research.

[31]  A. Makar,et al.  Hormone therapy in epithelial ovarian cancer. , 2000, Endocrine-related cancer.

[32]  G. Palumbo,et al.  17β-Estradiol Inhibits Apoptosis in MCF-7 Cells, Inducing bcl-2 Expression via Two Estrogen-Responsive Elements Present in the Coding Sequence , 2000, Molecular and Cellular Biology.

[33]  D. Mercola,et al.  Inhibition of Extracellular Signal-regulated Protein Kinase or c-Jun N-terminal Protein Kinase Cascade, Differentially Activated by Cisplatin, Sensitizes Human Ovarian Cancer Cell Line* , 1999, The Journal of Biological Chemistry.

[34]  J. Hayakawa,et al.  Role of mitogen-activated protein kinase/extracellular signal-regulated kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line. , 1999, Cancer research.

[35]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[36]  A. Wakeling,et al.  A potent specific pure antiestrogen with clinical potential. , 1991, Cancer research.

[37]  T. Nakamura,et al.  [Estrogen production in epithelial tumors of the ovary--identification of estrogen-synthesizing cells]. , 1989, Nihon Sanka Fujinka Gakkai zasshi.

[38]  O. Kjellgren,et al.  Plasma level of estradiol in patients with ovarian malignant tumors. , 1988, Gynecologic oncology.

[39]  A. Fattorossi,et al.  Activity of cisplatin and ICI 182,780 on estrogen receptor negative ovarian cancer cells: Cell cycle and cell replication rate perturbation, chromatin texture alteration and apoptosis induction , 2000, International journal of cancer.

[40]  B. O’Malley,et al.  Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.

[41]  S. Ueki,et al.  [Estrogen production in epithelial tumors of the ovary--localization of estrogen-synthesizing cells]. , 1989, Nihon Sanka Fujinka Gakkai zasshi.

[42]  P. Schwartz,et al.  Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial. , 1989, Cancer.